Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633115 | 0.79 | HTT (0.42) | GAAMAPTHTTKDM4ETSHR | |
| SCHEMBL4045244 | 0.78 | HTT (0.44) | GAAHTTLMNAMAPK10NPSR1 | |
| SCHEMBL2383891 | 0.78 | HTT (0.44) | GAAHTTKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL6755229 | 0.78 | HTT (0.44) | GAAHTTKMT2ANPSR1KDM4E | |
| SCHEMBL25836668 | 0.76 | HTT (0.42) | GAAMAPTHTTLMNAKMT2A | |
| SCHEMBL13208612 | 0.76 | HTT (0.42) | GAAMAPTHTTKMT2AKDM4E | |
| SCHEMBL16523107 | 0.74 | HTT (0.41) | GAAHTTKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL9951819 | 0.74 | HTT (0.41) | GAAHTTKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL7100600 | 0.74 | HTT (0.41) | GAAHTTKMT2AALDH1A1NPSR1 | |
| SCHEMBL9125151 | 0.74 | HTT (0.41) | GAAMAPTHTTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | claimed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | claimed |
| EP-0994896-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-04-30 | — | — | US | disclosed |
| EP-3178818-B1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2019-05-22 | — | — | EP | disclosed |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9850228-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3178818-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| US-6841684-B2 | For therapy of chronic pain, glaucoma or elevated intraocular pressure and other diseases with substantially reduced cardiovascular or sedative side effects | ALLERGAN, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1036065-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1413576-A2 | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors | Allergan, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | disclosed |
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ALLERGAN SALES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6329369-B1 | ANALGESICS FOR TREATING GLAUCOMA OR ELEVATED PRESSURE AND OTHER DISEASES WITH REDUCED SIDE EFFECTS BY TREATING A MAMMAL IN NEED THEREOF AN AGONIST OF ALPHA 2B OR ALPHA 2B/2C ADRENERGIC RECEPTOR | ALLERGAN SALES, INC. | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | GAA 930/4885MAPT 1957/4885HTT 1783/4885 |
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ADRA2B, ADRB2, ADRA2C | GAA 1908/4885MAPT 2787/4885HTT 2819/4885 |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | GAA 719/4885MAPT 3970/4885HTT 1684/4885 |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ADRB2, ADRB1, ADRA2B | GAA 4004/4885MAPT 4607/4885HTT 4492/4885 |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | GAA 930/4885MAPT 1957/4885HTT 1783/4885 |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | GAA 1632/4885MAPT 816/4885HTT 3592/4885 |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | GAA 930/4885MAPT 1957/4885HTT 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.